Asset
VELEDIMEX
ALAUNOS THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03636477 | phase1 | completed | 2018-06-18 | 2020-10-15 | Alaunos Therapeutics | A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 |
| NCT02423902 | phase1_2 | terminated | 2015-07-18 | 2016-07-19 | Alaunos Therapeutics | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer |
| NCT02026271 | phase1 | completed | 2015-06-01 | 2019-08-01 | Alaunos Therapeutics | A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma |
| NCT01703754 | phase2 | terminated | 2013-04-04 | 2014-08-07 | Alaunos Therapeutics | Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer. |
| NCT03679754 | phase1 | completed | 2018-09-05 | 2019-04-02 | Alaunos Therapeutics | Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 |
FDA applications (0)
This company has no applications containing this asset.